The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index; 1 of the 45 sources its claims cite were checked for support.
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Open accessAbstract
Background New drug treatments, clinical trials, and standards of quality for assessment of evidence justify an update of evidence-based recommendations for the pharmacological treatment of neuropathic pain. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), we revised the Special Interest Group on Neuropathic Pain (NeuPSIG) recommendations for the pharmacotherapy of neuropathic pain based on the results of a systematic review and meta-analysis.Methods Between April, 2013, and January, 2014, NeuPSIG of the International Association for the Study of Pain did a systematic review and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy for neuropathic pain, including studies published in peer-reviewed journals since January, 1966, and unpublished trials retrieved from ClinicalTrials.gov and websites of pharmaceutical companies. We used number needed to treat (NNT) for 50% pain relief as a primary measure and assessed publication bias; NNT was calculated with the fixed-effects Mantel-Haenszel method.Findings 229 studies were included in the meta-analysis. Analysis of publication bias suggested a 10% overstatement of treatment effects. Studies published in peer-reviewed journals reported greater effects than did unpublished studies (r(2) 9·3%, p=0·009). Trial outcomes were generally modest: in particular, combined NNTs were 6·4 (95% CI 5·2-8·4) for serotonin-noradrenaline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7·7 (6·5-9·4) for pregabalin; 7·2 (5·9-9·21) for gabapentin, including gabapentin extended release and enacarbil; and 10·6 (7·4-19·0) for capsaicin high-concentration patches. NNTs were lower for tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for lidocaine patches. Based on GRADE, final quality of evidence was moderate or high for all treatments apart from lidocaine patches; tolerability and safety, and values and preferences were higher for topical drugs; and cost was lower for tricyclic antidepressants and tramadol. These findings permitted a strong recommendation for use and proposal as first-line treatment in neuropathic pain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A. Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only.Interpretation Our results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain. Inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain. Modest efficacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profiling probably account for moderate trial outcomes and should be taken into account in future studies.Funding NeuPSIG of the International Association for the Study of Pain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
44 Own result · 24 Not checked yet · 8 Own interpretation · 5 No basis given · 3 Own method · 1 Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Studies published in peer-review journals reported greater effects than online studies (R2=9·3%, p<0·01).”
- Also stated in: § Risk of bias across studies · plain
“Using meta-regression, we identified that studies published in peer-review journals reported greater treatment effects (OR=2·2, 95% CI 1·5–3·0, n=153; adjusted R2=9·3%, p<0·01) than studies identified via online repositories (OR=1·4, 1·0–1·9, n=17).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plaincorrelationaln = 153 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Risk of bias across studies · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“6·3 (95 % CI 5·0–8·3) for gabapentin”
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
“Combined NNT was 6·3 (5·0–8·3) for gabapentin and 8·3 (6·2–13) for gabapentin ER/enacarbil.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In total 229 studies were included.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Data for cannabinoids, tapentadol, drug combinations, and several other antiepileptics, antidepressants and topical drugs were inconclusive.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“7·7 (95 % CI 6·5–9·4) for pregabalin”
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
“Combined NNT was 7·7 (6·5–9·4) and NNH was 13·9 (11·6–17·4).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“NNTs were 3·6 (95 % CI 3·0–4·4) for tricyclic antidepressants (TCAs)”
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
“Combined NNT (15 studies) was 3·6 (3·0–4·4) and NNH was 13·4 (9·3–24·4).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Trial outcomes were generally modest even for effective drugs”
- Also stated in: § Discussion · plain
“Results of quantitative data for individual drugs, showing NNT for 50 % pain relief ranging from around 4 to 10 across most positive trials, emphasizes the overall modest study outcomes in neuropathic pain.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“6·4 (95 % CI 5·2–8·4) for serotonin- noradrenaline reuptake inbibitor (SNRI) antidepressants duloxetine and venlafaxine”
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
“Combined NNT was 6·4 (5·2–8·4) and NNH was 11·8 (9·5–15·2).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Analysis of publication bias suggested a 10% overstatement of treatment effects.”
- Also stated in: § Risk of bias across studies · hedged
“This suggests a 10% relative overstatement of treatment effects.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Risk of bias across studies · hedged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Final quality of evidence was lower for lidocaine patches and BTX-A.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 37
Every source the paper cites for this claim was checked and supports it.
In the paper
“The systematic review of the literature compiled with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.22”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Procedures
What the sources say
- Supportedcites [22] Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med source
The PRISMA Statement section identifies PRISMA as a 27-item checklist and four-phase flow diagram for reporting systematic reviews. The citation identifies the reporting standard the citing authors say they followed; it does not serve as an independent audit of their review. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Tolerability/safety and values/preferences were high for lidocaine patches and lower for opioids and TCAs.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Findings
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fifty-five percent of the trials were conducted in diabetic painful polyneuropathy or postherpetic neuralgia.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Study selection and characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we found that high-concentration capsaicin patches were the most susceptible to publication bias, ie, a new study with less than 400 participants with no effect may increase the NNT to an unacceptable level.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified 13 trials of strong opioids using mainly oxycodone (10–120 mg/day) and morphine (90–240mg/day) in peripheral neuropathic pain. The final quality of evidence was moderate. Ten trials were positive: combined NNT was 4·3 (3·4–5·8) and NNH was 11·7 (8·4–19·3).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The trim and fill method suggested 34 theoretical missing studies (figure 3c) and adjusted our effect size from an OR of 1·8 (95% CI 1·7–1·9) to 1·6 (95% CI 1·5–1·7).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Risk of bias across studies
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It was lower (average 3–4) for older studies of TCAs and capsaicin and higher (average >4) for more recent studies (pregabalin, gabapentin, SNRIs, opioids, capsaicin high-concentration patches).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Risk of bias in individual trials
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Long-term controlled studies were lacking and few lasted longer than 12 weeks, with the longest lasting 24 weeks.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Topiramate, zonisamide, and oxcarbazepine/carbamazepine had the poorest safety profile, with combined NNH of 6·3 (5·1–8·0), 2·0 (1·3–4·6), and 5·5 (4·3–7·9), respectively.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified 14 RCTs of gabapentin (900–3600 mg/day) (nine positive) and 6 RCTs of gabapentin ER or gabapentin enacarbil (1200–3600 mg/day) (four positive).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified one negative study and one positive enrichment study of tapentadol ER: the latter had potential bias (probable unblinding of the patients enrolled in the double blind period) and high NNT (in 67 % of the patients responding to the open phase).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was no evidence for a dose-response effect.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: fails — The authors may not put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The authors may not put it forward as true. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 18 out of 25 placebo-controlled RCTs of pregabalin (150–600 mg/day) were positive, with high final quality of evidence.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All seven studies of tramadol (mainly tramadol ER up to 400 mg daily) were positive, with moderate final quality of evidence. Combined NNT was 4·7 (3·6–6·7), with the highest NNT (6·4) in the largest study. Combined NNH was 12·6 (8·4–25·3).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five out of seven studies (in postherpetic neuralgia or HIV-related painful polyneuropathy) reported sustained efficacy of a single application of high-concentration capsaicin patch (8%)”
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
“The final quality of evidence was high. Combined NNT was 10·6 (7·4–19).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Quantitative data for individual drugs or drug classes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 165 published or unpublished trials with dichotomous data were analysed for publication bias.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Risk of bias across studies
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we identified only one small negative study of 5% lidocaine patches in postsurgical neuropathic pain and two enriched enrolment studies in postherpetic neuralgia. The smaller study (32 patients) was positive, the larger study (263 patients) was negative in the ITT population, but positive in the per protocol population.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Six RCTs evaluated the efficacy of a single administration of BTX-A (50–200 units subcutaneously in the painful area) in peripheral neuropathic pain. The smaller studies had a positive primary outcome (NNT of 1·9 (1·5–2·4) for four studies) with a very low placebo effect, but one large unpublished study was negative.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Safety was good (NNH 25·6 (15·3–78·6) for gabapentin and 31·9 (17·1–230) for gabapentin ER).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Few relevant trials appeared since our meta-analysis, but none affected the recommendations (appendix 11).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > GRADE recommendations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results of quantitative data for individual drugs, showing NNT for 50 % pain relief ranging from around 4 to 10 across most positive trials, emphasizes the overall modest study outcomes in neuropathic pain.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of seven RCTs of various combination therapy in neuropathic pain (appendices 4 and 6), two found that gabapentin combined to morphine or to nortriptyline was superior to monotherapy (and to placebo in one study) at reduced dosages and with no more side effects.”
- Also stated in: § Combination therapy · plain
“However the largest study (not placebo controlled) showed no difference in efficacy or side effects between pregabalin combined to duloxetine at moderate dosages (300 mg pregabalin, 60 mg duloxetine daily) and monotherapy at high dosages (600 mg pregabalin, 120 mg duloxetine daily) in patients not responsive to monotherapy at moderate dosages.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Combination therapy
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Combination therapy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximum effectiveness seemed associated with 180 mg morphine or equivalent (no additional benefit for higher doses).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Quantitative data for individual drugs or drug classes
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Limited efficacy, large placebo responses, inadequate diagnostic criteria and poor phenotypic profiling probably account for modest trial outcomes and should be taken into account in future studies.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Abstract > Interpretation
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Adequate diagnostic criteria for neuropathic pain are lacking.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We used a standardized review and data extraction protocol (unpublished, appendices 2 and 3).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“The GRADE classification was used to assess recommendations based on a group of RCTs pertaining to the same drug or drug class when relevant (ie TCAs)17,18 with final quality of evidence rated as strong or weak for the treatment, against the treatment, or inconclusive”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Evidence summary and reporting
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“Studies were assessed for methodological quality using the five-point Oxford Quality Scale25 by two independent authors (appendix 1).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Procedures
What the sources say
- Not checked yetcites [25] Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Here, a minimum score of 2 out of 5 (randomised and double-blind study) was required for inclusion.25”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Procedures
What the sources say
- Not checked yetcites [25] Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was introduced in 200017,18 and has received widespread international acceptance.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Introduction
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We also assessed serious risk of bias relating to lack of allocation concealment, incomplete accounting of outcome events, selective outcome reporting, stopping early for benefit, use of invalidated outcome measures and carryover effects in crossover trials.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“An assessment of publication bias was performed using funnel plots,26 Egger’s regression,27 and Duval and Tweedie’s non-parametric trim and fill approach.28”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Statistics
What the sources say
- Not checked yetcites [26] Light, 1984
- Not checked yetcites [27] Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ source
- Not checked yetcites [28] Duval, 2000, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The extent to which the observed variability (heterogeneity) in treatment effects is explained by publication in a peer-reviewed journal was assessed using meta-regression.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Statistics
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Additionally, we estimated the susceptibility to bias for individual drug classes.29,30”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Methods > Statistics
What the sources say
- Not checked yetcites [29] Moore, 2008, Managing potential publication bias
- Not checked yetcites [30] Moore, 2011, Single dose oral analgesics for acute postoperative pain in adults, Cochrane Database Syst Rev source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This may be due to lack of diagnostic accuracy and relatively ineffective drugs, but also insufficient knowledge about effective drugs and their appropriate use in clinical practice.8”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Introduction
What the sources say
- Not checked yetcites [8] Martinez, 2014, Adherence of French GPs to Chronic Neuropathic Pain Clinical Guidelines: Results of a Cross-Sectional, Randomized, “e” Case-Vignette Survey, PLoS One source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, they may not be applicable for trigeminal neuralgia, for which we could extract only one study complying with our inclusion criteria.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > GRADE recommendations
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This may be due to large placebo responses in HIV-related neuropathy trials,45 a distinct clinical phenotype in subgroups of patients with radiculopathy,46 or psychological/psychosocial comorbidites, often neglected in large trials.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, none of the studies assessed pediatric neuropathic pain, and the present guidelines therefore only apply to adults.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > GRADE recommendations
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Publication bias may be present if studies with positive results are published while those with no data or negative results are not.29 It may lead to major overestimation of efficacy in therapeutic studies.47”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [29] Moore, 2008, Managing potential publication bias
- Not checked yetcites [47] Thornton, 2000, Publication bias in meta-analysis: its causes and consequences, J Clin Epidemiol source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly these recommendations do not apply to acute pain or acute pain exacerbation.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > GRADE recommendations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Side effects may, however, to some degree depend on the aetiology, eg, drugs with CNS-related side effects may be less tolerated in patients with CNS lesions.44”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [44] Cepeda, 2012, Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis, Pain Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was generally no evidence for efficacy of particular drugs in specific conditions. Therefore these recommendations apply to neuropathic pain in general.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > GRADE recommendations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Few studies included cancer-related neuropathic pain; the recommendations for the use of opioids may be different in certain cancer populations.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > GRADE recommendations
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Inadequate response of neuropathic pain to drug therapy constitutes a highly unmet need and may have substantial consequences in terms of psychological or social adjustment.49”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [49] Treede, 2008, Neuropathic pain: redefinition and a grading system for clinical and research purposes, Neurology source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neither individual studies nor their statistical combination demonstrated significant differences in efficacy or safety between drugs. Despite limited sample sizes and unknown assay sensitivity in the lack of placebo groups, results suggest comparable efficacy across first- and most second-line recommended treatments.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Results > Comparative drug trials
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This supports the robustness of a meta-analysis taking into account unpublished trials, and suggests that effect sizes were overestimated in previous meta-analyses of pharmacotherapy for neuropathic pain.”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It has recently been reported that the drug treatment of postherpetic neuralgia by primary care physicians was roughly consistent with the US recommendations issued some years before.6”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [6] Dworkin, 2012, Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations?, Pain source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“One major issue is the placebo response which seems to have increased in recent trials of neuropathic pain and may lead to an underestimation of drug effects.51”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [51] Demant, 2014, The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study, Pain source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“We provide a weak recommendation against the use of cannabinoids in neuropathic pain, mainly because of negative results, potential misuse, abuse, diversion and long term mental health risks particularly in susceptible individuals.66–71”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [66] Di, 2009, High-potency cannabis and the risk of psychosis, Br J Psychiatry source
- Not checked yetcites [67] Kuepper, 2011, Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study, BMJ source
- Not checked yetcites [68] Hall, 2011, Cannabis and the increased incidence and persistence of psychosis, BMJ source
- Not checked yetcites [69] Davis, 2013, Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions, Schizophr Res source
- Not checked yetcites [70] Gilman, 2014, Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users, J Neurosci source
- Not checked yetcites [71]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The use of diagnostic algorithms for neuropathic pain53 and screening tools54 should contribute to reducing diagnostic heterogeneity (Table 4).”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [53] Bouhassira, 2014, Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study, Pain source
- Not checked yetcites [54] Farrar, 2014, Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study, Pain source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Rests on an assumption: Adequate diagnostic criteria for neuropathic pain are lacking.
In the paper
“Capsaicin patches are proposed as second-line for peripheral neuropathic pain because of high quality of evidence, but modest effect size, training requirements, and potential safety concerns on sensation with long-term use.65”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [65] Semple, 2005, Cannabis as a risk factor for psychosis: systematic review, J Psychopharmacol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lastly, a largely debated issue concerns the heterogeneity of patient phenotypes in clinical trials, which may reflect various underlying mechanisms.55–57”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
- Not checked yetcites [55] Dworkin, 2013, Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-analysis, Neurology source
- Not checked yetcites [56] Lund, 2014, Randomised controlled trials may underestimate drug effects: balanced placebo trial design, PLoS One source
- Not checked yetcites [57] Attal, 2011, Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome?, Eur J Pain source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Placebo response has been found to be higher in HIV-related neuropathies,45 and in patients with low or variable pain scores at inclusion.52 Conversely it seems to be lower in postherpetic neuralgia.45”
§ Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations > Discussion
What the sources say
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Neuropathic pain is hard to treat.
“Neuropathic pain is difficult to treat.”
The paper relies on this without support.
Large unpublished trials that were previously hidden can now be found on clinicaltrials.gov and pharmaceutical industry websites.
“Previously hidden and unpublished large trials can now be identified on the web (clinicaltrials.gov, pharmaceutical industry websites)”
The paper relies on this without support.
Topical agents are not known to be relevant for central neuropathic pain.
“Topical agents have no known relevance for use in central neuropathic pain, and this is clearly stated in our recommendations.”
The paper relies on this without support.
Adequate diagnostic criteria for neuropathic pain are lacking.
“Another issue concerns the lack of adequate diagnostic criteria for neuropathic pain (available on request for individual trials).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, medical treatment comes with many side effects [5].”
From Virtual walking therapy in neuropathic spinal cord injury pain: a feasibility study (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent reviews conclude that there is a lack of evidence for the impact of pharmacological and non-pharmacological treatments [5].”
From Virtual walking therapy in neuropathic spinal cord injury pain: a feasibility study (2024) · cites this paper as [5]
Experimental — accuracy not yet measured
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Cited by
Sorted by citations
Items 201–300 of 1,007
Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank
Baskozos, G., Hébert, H. L., Pascal, M. M. V., Themistocleous, A. C., Macfarlane, G. J., Wynick, D., Bennett, D. L. H., & Smith, B. H. (2023) · PAIN Reports · doi:10.1097/pr9.0000000000001066 · Cited by 134
Self-citationOnakpoya, I. J., Thomas, E. T., Lee, J. J., Goldacre, B., & Heneghan, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023600 · Cited by 132
Circuitry and plasticity of the dorsal horn – Toward a better understanding of neuropathic pain
West, S. J., Bannister, K., Dickenson, A. H., & Bennett, D. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.020 · Cited by 129
The Dorsal Root Ganglion as a Therapeutic Target for Chronic Pain
Liem, L., van Dongen, E., Huygen, F. J. P. M., Staats, P. S., & Kramer, J. (2016) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000408 · Cited by 120
Mu, A., Weinberg, E. L., Moulin, D. E., & Clarke, H. A. (2017) · Europe PMC (PubMed Central) · Cited by 122
Häuser, W., Morlion, B. J., Vowles, K. E., Bannister, K., Buchser, E., Casale, R., Chenot, J., Chumbley, G. M., Drewes, A. M., Dom, G., et al. (2021) · European Journal of Pain · doi:10.1002/ejp.1736 · Cited by 123
Diabetic peripheral neuropathy may not be as its name suggests
Tesfaye, S. H., Selvarajah, D., Gandhi, R. A., Greig, M., SHILLO, P. R., Fang, F., & Wilkinson, I. D. (2015) · Pain · doi:10.1097/j.pain.0000000000000465 · Cited by 122
Häggman‐Henrikson, B., Alstergren, P. J., Davidson, T., Högestätt, E. D., Östlund, P., Tranæus, S., Vitols, S., & List, T. (2017) · Journal of Oral Rehabilitation · doi:10.1111/joor.12539 · Cited by 128
Depression Prevalence in Neuropathic Pain and Its Impact on the Quality of Life
Cherif, F., Zouari, H. G., Cherif, W., Hadded, M., Cheour, M., & Damak, R. (2020) · Pain Research and Management · doi:10.1155/2020/7408508 · Cited by 124
Nijs, J., Kosek, E., Chiarotto, A., Cook, C. E., Danneels, L. A., Fernández‐de‐las‐Peñas, C., Hodges, P. W., Koes, B. W., Louw, A., Ostelo, R., et al. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00324-7 · Cited by 136
van Nooten, F. E., Treur, M., Pantiri, K., Stoker, M., & Charokopou, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.02.010 · Cited by 117
Moisset, X., Pereira, B., de Andrade, D. C., Fontaine, D., Lantéri‐Minet, M., & Mawet, J. (2020) · The Journal of Headache and Pain · doi:10.1186/s10194-020-01204-4 · Cited by 118
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
Politei, J. M., Bouhassira, D., Germain, D. P., Goizet, C., Guerrero-Sola, A., Hilz, M. J., Hutton, E. J., Karaa, A., Liguori, R., Üçeyler, N., et al. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12542 · Cited by 123
Neuropathic pain and SCI: Identification and treatment strategies in the 21st century
Hatch, M. N., Cushing, T. R., Carlson, G. D., & Chang, E. Y. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.11.018 · Cited by 116
Fandel, T. M., Trivedi, A., Nicholas, C. R., Zhang, H., Chen, J., Martinez, A. F., Noble-Haeusslein, L. J., & Kriegstein, A. R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.08.020 · Cited by 125
Treating Painful Diabetic Peripheral Neuropathy: An Update.
Snyder, M. J., Gibbs, L. M., & Lindsay, T. J. (2016) · PubMed · Cited by 115
The role of quantitative sensory testing in the prediction of chronic pain
Treede, R. (2019) · Pain · doi:10.1097/j.pain.0000000000001544 · Cited by 115
Zilliox, L. A. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000462 · Cited by 119
Small fiber neuropathy: diagnosis, causes, and treatment
Sène, D. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2017.11.002 · Cited by 113
Zheng, J., Jiang, Y., Xu, L., Ma, L., Liu, F., Cui, S., Cai, J., Liao, F., Wan, Y., & Yi, M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3333-16.2017 · Cited by 117
Diabetic Sensory and Motor Neuropathy
Vinik, A. I. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1503948 · Cited by 113
The Pharmacological Therapy of Chronic Neuropathic Pain
Binder, A., & Baron, R. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0616 · Cited by 113
Self-citationMental health of long‐term survivors of childhood and young adult cancer: A systematic review
Friend, A. J., Feltbower, R. G., Hughes, E., Dye, K. P., & Glaser, A. (2018) · International Journal of Cancer · doi:10.1002/ijc.31337 · Cited by 113
Neuroimmune Mechanisms Underlying Neuropathic Pain: The Potential Role of TNF-α-Necroptosis Pathway
Duan, Y.-W., Chen, S., Li, Q., & Zang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137191 · Cited by 117
Role of Vagus Nerve Stimulation in the Treatment of Chronic Pain
Shao, P., Li, H., Jiang, J., Guan, Y., Chen, X., & Wang, Y. (2023) · NeuroImmunoModulation · doi:10.1159/000531626 · Cited by 118
Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.
Ibrahim, M. M., Patwardhan, A., Gilbraith, K. B., Moutal, A., Yang, X., Chew, L. A., Largent-Milnes, T., Malan, T. P., Vanderah, T. W., Porreca, F., et al. (2017) · Pain · doi:10.1097/j.pain.0000000000000767 · Cited by 123
Attal, N., Ayache, S. S., de Andrade, D. C., Mhalla, A., Baudic, S., Jazat, F., Ahdab, R., Somensi, D. N., Sorel, M., Lefaucheur, J., et al. (2016) · Pain · doi:10.1097/j.pain.0000000000000510 · Cited by 111
Self-citationPractice review: Evidence-based and effective management of pain in patients with advanced cancer
Chapman, E., Edwards, Z., Boland, J. W., Maddocks, M. M., Fettes, L., Malia, C., Mulvey, M. R., & Bennett, M. (2020) · Palliative Medicine · doi:10.1177/0269216319896955 · Cited by 115
Neuropathic Pain: the Dysfunction of Drp1, Mitochondria, and ROS Homeostasis
Dai, C., Guo, Y., & Chu, X.-Y. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00257-2 · Cited by 111
Calcium channel modulation as a target in chronic pain control
Patel, R., Montagut‐Bordas, C., & Dickenson, A. H. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13789 · Cited by 110
Vinik, A. I., Perrot, S., Vinik, E. J., Pazdera, L., Jacobs, H., Stoker, M., Long, S., Snijder, R. J., van der Stoep, M., Ortega, E., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0752-7 · Cited by 109
Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain
Haanpää, M. L., Cruccu, G., Nurmikko, T. J., McBride, W. T., Axelarad, A. D., Bosilkov, A., Chambers, C., Ernault, É., & Abdulahad, A. (2015) · European Journal of Pain · doi:10.1002/ejp.731 · Cited by 110
Self-citationOptogenetic and chemogenetic strategies for sustained inhibition of pain
Iyer, S. M., Vesuna, S. S., Ramakrishnan, C., Huynh, K., Young, S., Berndt, A., Lee, S. Y., Gorini, C., Deisseroth, K. A., & Delp, S. L. (2016) · Scientific Reports · doi:10.1038/srep30570 · Cited by 109
Kato, J., Matsui, N., Kakehi, Y., Murayama, E., Ohwada, S., & Sugihara, M. (2019) · Pain · doi:10.1097/j.pain.0000000000001501 · Cited by 108
Pregabalin as a Pain Therapeutic: Beyond Calcium Channels
Alles, S. R. A., Cain, S. M., & Snutch, T. P. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00083 · Cited by 120
Comparative pharmacology and toxicology of tramadol and tapentadol
Faria, J., Barbosa, J., Moreira, R. F., Queirós, O., Carvalho, F. D., & Dinis‐Oliveira, R. J. (2018) · European Journal of Pain · doi:10.1002/ejp.1196 · Cited by 107
Voltage-gated Na+ currents in human dorsal root ganglion neurons
Zhang, X., Priest, B. T., Belfer, I., & Gold, M. S. (2017) · eLife · doi:10.7554/elife.23235 · Cited by 106
Galley, H. F., McCormick, B., Wilson, K. L., Lowes, D. A., Colvin, L., & Torsney, C. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12444 · Cited by 103
Bouhassira, D., Luporsi, É., & Krakowski, I. (2017) · Pain · doi:10.1097/j.pain.0000000000000895 · Cited by 105
Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic
Attal, N., Martinez, V., & Bouhassira, D. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000884 · Cited by 107
Self-citationTreating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Rethinking chronic pain in a primary care setting
Stanos, S. P., Brodsky, M., Argoff, C. E., Clauw, D. J., D’Arcy, Y. M., Donevan, S. D., Gebke, K. B., Jensen, M. P., Clark, E. L., McCarberg, B. H., et al. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1188319 · Cited by 107
Kremer, M., Yalçın, İ., Goumon, Y., Wurtz, X., Nexon, L., Daniel, D., Megat, S., Ceredig, R. A., Ernst, C., Turecki, G., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1004-18.2018 · Cited by 104
Capturing Novel Non-opioid Pain Targets
Woolf, C. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.06.017 · Cited by 110
Teixeira-Santos, L., Albino‐Teixeira, A., & Pinho, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105280 · Cited by 108
U.S. Trends in Registration for Medical Cannabis and Reasons for Use From 2016 to 2020
Boehnke, K. F., Dean, O., Haffajee, R. L., & Hosanagar, A. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0217 · Cited by 109
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment
Ferraro, M. C., O'Connell, N. E., Sommer, C., Göebel, A., Bultitude, J. H., Cashin, A. G., Moseley, G. L., & McAuley, J. H. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00076-0 · Cited by 103
Cannabis constituent synergy in a mouse neuropathic pain model
Casey, S. L., Atwal, N., & Vaughan, C. W. (2017) · Pain · doi:10.1097/j.pain.0000000000001051 · Cited by 105
Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages
Kiguchi, N., Kobayashi, D., Saika, F., Matsuzaki, S., & Kishioka, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112296 · Cited by 106
Cancer-Related Neuropathic Pain
Edwards, H. L., Mulvey, M. R., & Bennett, M. (2019) · Cancers · doi:10.3390/cancers11030373 · Cited by 102
Antidepressants for Preventive Treatment of Migraine
Burch, R. C. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0557-2 · Cited by 111
Sensitization of the Nociceptive System in Complex Regional Pain Syndrome
Reimer, M., Rempe, T., Diedrichs, C., Baron, R., & Gierthmühlen, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154553 · Cited by 101
Self-citationKhan, M. T. I., Nishi, S. E., Hassan, S. N., Islam, M. A., & Gan, S. H. (2017) · Pain Research and Management · doi:10.1155/2017/7438326 · Cited by 104
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Clauw, D. J., Goesling, J., & Williams, D. A. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.05.009 · Cited by 107
Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice
Sahn, J. J., Mejia, G. L., Ray, P. R., Martin, S. F., & Price, T. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00200 · Cited by 98
Bäckryd, E., Lind, A., Thulin, M., Larsson, A. O., Gerdle, B. U. C., & Gordh, T. (2017) · Pain · doi:10.1097/j.pain.0000000000001061 · Cited by 106
Targeting Serotonin1A Receptors for Treating Chronic Pain and Depression
Haleem, D. J. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190811161807 · Cited by 103
The Genetics of Neuropathic Pain from Model Organisms to Clinical Application
Calvo, M., Davies, A. J., Hébert, H. L., Weir, G. A., Chesler, E. J., Finnerup, N. B., Levitt, R. C., Smith, B. H., Neely, G. G., Costigan, M., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.018 · Cited by 105
Self-citationBalanaser, M., Carley, M. E., Baron, R., Finnerup, N. B., Moore, A., Rowbotham, M. C., Chaparro, L. E., & Gilron, I. (2022) · Pain · doi:10.1097/j.pain.0000000000002688 · Cited by 101
Self-citationFerreira, G. E., Shaheed, C. A., Underwood, M. R., Finnerup, N. B., Day, R. O., McLachlan, A. J., Eldabe, S. S., Zadro, J. R., & Maher, C. G. (2023) · BMJ · doi:10.1136/bmj-2022-072415 · Cited by 116
Self-citationInterventions for Neuropathic Pain: An Overview of Systematic Reviews
Došenović, S., Kadić, A. J., Miljanović, M., Biocić, M., Borić, K., Ćavar, M., Markovina, N., Vučić, K., & Puljak, L. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001998 · Cited by 99
Montero‐Oleas, N., Arévalo-Rodríguez, I., Núñez-González, S., Viteri-García, A. A., & Simancas‐Racines, D. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-019-2803-2 · Cited by 98
Chen, X.-J., Wang, L., & Song, X.-Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110003 · Cited by 99
Baptista, A. F., Fernandes, A. M., Sá, K. N., Okano, A. H., Brunoni, A. R., Lara-Solares, A., Iskandar, A. J., Guerrero, C., Amescua-García, C., Kraychete, D. C., et al. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000692 · Cited by 101
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain
Petzke, F. W., Tölle, T. R., Fitzcharles, M., & Häuser, W. (2021) · CNS Drugs · doi:10.1007/s40263-021-00879-w · Cited by 106
Exercise for Neuropathic Pain: A Systematic Review and Expert Consensus
Zhang, Y., Hu, H., Xiong, Y.-C., Peng, C., Hu, L., Kong, Y.-Z., Wang, Y., Guo, J., Bi, S., Li, T.-S., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756940 · Cited by 98
Chloride Homeostasis Critically Regulates Synaptic NMDA Receptor Activity in Neuropathic Pain
Li, L., Chen, S.-R., Chen, H., Wen, L., Hittelman, W. N., Xie, J.-D., & Pan, H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.039 · Cited by 98
Prevention and Treatment of Chronic Postsurgical Pain: A Narrative Review
Steyaert, A., & Lavand’homme, P. (2018) · Drugs · doi:10.1007/s40265-018-0866-x · Cited by 97
Virtual reality for spinal cord injury-associated neuropathic pain: Systematic review
Chi, B., Chau, B., Yeo, E., & Ta, P. (2019) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2018.09.006 · Cited by 97
PKM2 is involved in neuropathic pain by regulating ERK and STAT3 activation in rat spinal cord
Wang, B., Liu, S. J., Fan, B., Xu, X., Chen, Y., Lu, R., Xu, Z., & Liu, X. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0836-4 · Cited by 101
Expert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients
Kuhn, M. A., Gillespie, M. B., Ishman, S. L., Ishii, L. E., Brody, R. A., Cohen, E. E. W., Dhar, S. I., Hutcheson, K. A., Jefferson, G. D., Johnson, F., et al. (2023) · Otolaryngology · doi:10.1002/ohn.302 · Cited by 98
Managing Neuropathic Pain in Dogs
Moore, S. A. (2016) · Frontiers in Veterinary Science · doi:10.3389/fvets.2016.00012 · Cited by 96
Boakye, P. A., Tang, S.-J., & Smith, P. A. (2021) · Frontiers in Pain Research · doi:10.3389/fpain.2021.698157 · Cited by 102
Strategies to Treat Chronic Pain and Strengthen Impaired Descending Noradrenergic Inhibitory System
Hayashida, K., & Obata, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040822 · Cited by 101
GPR160 de-orphanization reveals critical roles in neuropathic pain in rodents
Yosten, G. L. C., Harada, C. M., Haddock, C. J., Giancotti, L. A., Kolar, G. R., Patel, R., Guo, C. H., Chen, Z., Zhang, J., Doyle, T. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133270 · Cited by 95
Current status of GABA receptor subtypes in analgesia
Qian, X., Zhao, X., Yu, L., Yin, Y., Zhang, X., Wang, L., Li, J., Zhu, Q., & Luo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115800 · Cited by 95
Combination of morphine with nortriptyline for neuropathic pain
Gilron, I., Tu, D., Holden, R. R., Jackson, A. C., & Dumerton-Shore, D. (2015) · Pain · doi:10.1097/j.pain.0000000000000149 · Cited by 94
Self-citationNeuropeptide Y and its Involvement in Chronic Pain
Diaz‐delCastillo, M., Woldbye, D. P. D., & Heegaard, A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.08.050 · Cited by 95
Pain management in patients with chronic kidney disease and end-stage kidney disease
Roy, P. J., Weltman, M. R., Dember, L. M., Liebschutz, J. M., & Jhamb, M. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000646 · Cited by 95
Bruce, R. D., Merlin, J. S., Lum, P. J., Ahmed, E., Alexander, C. S., Corbett, A., Foley, K. M., Leonard, K., Treisman, G. J., & Selwyn, P. A. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix636 · Cited by 94
Ortiz-Catalan, M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00748 · Cited by 94
Pain and depression comorbidity causes asymmetric plasticity in the locus coeruleus neurons
Llorca-Torralba, M., Camarena-Delgado, C., Suárez‐Pereira, I., Bravo, L., Mariscal, P., Garcia-Partida, J. A., López‐Martín, C., Wei, H., Pertovaara, A., Micó, J. A., et al. (2021) · Brain · doi:10.1093/brain/awab239 · Cited by 95
Ji, G., Zhang, W. Y., Mahimainathan, L., Narasimhan, M., Kiritoshi, T., Fan, X., Wang, J., Green, T. A., & Neugebauer, V. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2468-16.2016 · Cited by 92
Jaracz, J., Gattner, K., Jaracz, K., & Górna, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0328-5 · Cited by 94
Kane, C., Mulvey, M. R., Wright, S., Craigs, C., Wright, J. M., & Bennett, M. (2017) · Palliative Medicine · doi:10.1177/0269216317711826 · Cited by 90
An update and systematic review on drug therapies for the treatment of refractory chronic cough
Ryan, N., Vertigan, A. E., & Birring, S. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1462795 · Cited by 90
Core Outcome Measures in Preclinical Assessment of Candidate Analgesics
Negus, S. S. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017210 · Cited by 91
Torrance, N., Veluchamy, A., Zhou, Y., Fletcher, E. H., Moir, E., Hébert, H. L., Donnan, P. T., Watson, J., Colvin, L., & Smith, B. H. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.05.017 · Cited by 90
Self-citationZádori, Z., Király, K. P., Al‐Khrasani, M., & Gyires, K. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108327 · Cited by 92
Diabetic peripheral neuropathy essentials: a narrative review
Chang, M. C., & Yang, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-693 · Cited by 90
Reducing CXCR4-mediated nociceptor hyperexcitability reverses painful diabetic neuropathy
Jayaraj, N. D., Bhattacharyya, B. J., Belmadani, A. A., Ren, D., Rathwell, C. A., Hackelberg, S., Hopkins, B. E., Gupta, H. R., Miller, R. J., & Menichella, D. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci92117 · Cited by 90
Sommer, C., Geber, C., Young, P., Forst, R., Birklein, F., & Schoser, B. G. H. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0083 · Cited by 90
Translational neuropathic pain research: A clinical perspective
Bouhassira, D., & Attal, N. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.029 · Cited by 89
Self-citationWodarski, R., Delaney, A., Ultenius, C., Morland, R., Andrews, N., Baastrup, C., Bryden, L. A., Caspani, O., Christoph, T., Gardiner, N. J., et al. (2016) · Pain · doi:10.1097/j.pain.0000000000000657 · Cited by 95
Self-citationAsseyer, S., Cooper, G., & Paul, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00778 · Cited by 87
Brown, S., Johnston, B. C., Amaria, K., Watkins, J., Campbell, F. A., Pehora, C., & McGrath, P. A. (2016) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2016.05.039 · Cited by 89
Medical Cannabis for Neuropathic Pain
Lee, G., Grovey, B., Furnish, T. J., & Wallace, M. S. (2018) · Current Pain and Headache Reports · doi:10.1007/s11916-018-0658-8 · Cited by 87
Self-citationCannabinoids in Pain Management and Palliative Medicine
Häuser, W., Fitzcharles, M., Radbruch, L., & Petzke, F. W. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0627 · Cited by 89
Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain
Blair, H. A. (2018) · Drugs · doi:10.1007/s40265-018-0982-7 · Cited by 87
A prototype closed-loop brain–machine interface for the study and treatment of pain
Zhang, Q., Hu, S., Talay, R. S., Xiao, Z., Rosenberg, D., Liu, Y., Sun, G., Li, A., Caravan, B., Singh, A., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00736-7 · Cited by 93
Metadata
- Authors
- Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., Kamerman, P. R., Lund, K., Moore, A., Raja, S. N., Rice, A. S. C., Rowbotham, M., Sena, E., Siddall, P., Smith, B. H., & Wallace, M.
- Affiliations
- Aarhus University (DK)
- Inserm (FR)
- Washington University in St. Louis (US)
- Tufts Medical Center (US)
- University Hospital Schleswig-Holstein (DE)
- University of Rochester Medicine (US)
- Queen's University (CA)
- Helsinki University Hospital (FI)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Churchill Hospital (GB)
- Johns Hopkins University (US)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- University of California, San Francisco (US)
- Florey Institute of Neuroscience and Mental Health (AU)
- The University of Sydney (AU)
- University of Dundee (GB)
- University of California San Diego (US)
- Corresponding author
- Attal, Nadine
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 14
- Issue
- 2
- Pages
- 162-173
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC4493167
- OpenAlex
- W2104818454
- Cited by
- 3,980
- References
- 80
- Citations by year
- 2026: 316 · 2025: 363 · 2024: 399 · 2023: 362 · 2022: 367 · 2021: 447 · 2020: 384 · 2019: 367 · 2018: 336 · 2017: 305 · 2016: 228 · 2015: 99
- FWCI
- 39.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Medtronic
- Sanofi Pasteur
- Advanced Scientific Computing Research
- Dunhill Medical Trust
- National Institutes of Health
- Biogen Idec
- Deutsche Forschungsgemeinschaft
- U.S. Food and Drug Administration
- AbbVie
- National Institute of Academic Anaesthesia
- Novartis
- International Fibrodysplasia Ossificans Progressiva Association
- Pfizer
- Merck Sharp and Dohme
- National Centre for the Replacement Refinement and Reduction of Animals in Research
- Astellas Pharma US
- Wellcome Trust
- AstraZeneca
- Westminster Medical School Research Trust
- Merck
- Bundesministerium für Bildung und Forschung
- Allergan
- Eisai
- Eli Lilly and Company
- Boehringer Ingelheim
- Bayer Schering
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- neuropathic pain, pharmacotherapy, duloxetine, pregabalin, gabapentin, tricyclic antidepressants, tramadol, botulinum toxin type A, lidocaine patch, capsaicin patch, topical analgesics, number needed to treat, publication bias, treatment guidelines, first-line therapy, safety and tolerability, cost-effectiveness, adults, quality of evidence
- MeSH terms
- Adult, Analgesics, Opioid, Antidepressive Agents, Tricyclic, Humans, Neuralgia, Randomized Controlled Trials as Topic, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
